Denali Q2 2026 Earnings: AVLAYAH Launch Generates $3.6 Million

Denali Therapeutics (NASDAQ: DNLI) reported Q2 2026 results for the quarter ended June 30, with net product revenue of $3.6 million versus none a year earlier and diluted net loss per share of $0.68 versus $0.72. AVLAYAH recorded its first full quarter of commercial sales, while lower research spending was largely offset by launch-related growth in selling, general and administrative expenses. Denali held approximately $940 million in cash, cash equivalents and marketable securities at quarter-end, before receiving $195 million in gross proceeds from a Priority Review Voucher sale in July.

Core financial results

The quarter marked Denali’s transition from a clinical-stage biotechnology company to one generating product revenue. All reported revenue came from AVLAYAH following its FDA approval in March 2026.

Research and development expense declined because of lower spending on small-molecule programs and lower clinical costs for tividenofusp alfa. SG&A expense increased as Denali added personnel to support the AVLAYAH commercial launch.

Initial cost of goods sold was unusually low because AVLAYAH inventory manufactured before FDA approval had already been expensed through R&D. Consequently, the initial commercialization period reflects a lower average unit cost as that inventory is sold.

AVLAYAH commercial rollout and pipeline developments

AVLAYAH generated $3.6 million in its first full quarter of commercial availability. Denali said treatment interest was ahead of its internal expectations, although it did not quantify patient starts. The commercial team has reached approximately 80% of healthcare organizations treating eligible MPS II patients, while published commercial policies cover more than 50% of covered lives and 14 state Medicaid programs have published coverage.

The Phase 2/3 COMPASS study remains important to AVLAYAH’s longer-term outlook. It is intended to provide confirmatory evidence for the accelerated approval, support a potential U.S. label expansion to adults and contribute to future regulatory submissions outside the United States.

Beyond AVLAYAH, Denali advanced two Alzheimer’s disease candidates into clinical development, but it also reported a delay for DNL593 and a prior clinical setback for DNL151. The principal program updates and expected milestones are summarized below.

Takeda also terminated its DNL593 collaboration during the quarter. Denali said that decision reflected Takeda’s strategic considerations and was not related to efficacy or safety data.

Lower interest income offset the operating-loss improvement

Product revenue and slightly lower total operating expenses reduced Denali’s operating loss by approximately $4.4 million. However, interest and other income fell to $3.0 million from $10.8 million, more than offsetting the operating improvement and causing the total net loss to widen by approximately $3.4 million.

The loss per share nevertheless narrowed because the weighted-average diluted share count increased to 187.3 million from 171.4 million. This explains why the per-share result improved even though the absolute net loss increased.

Denali ended June with approximately $940 million in cash, cash equivalents and marketable securities. The company subsequently received $195 million in gross proceeds from selling the Priority Review Voucher awarded after AVLAYAH’s approval, lifting its pro forma cash and securities balance above $1.1 billion.

Guidance

Denali projected Q3 2026 AVLAYAH net product revenue of $10 million to $12 million. That range represents a clear sequential increase from the $3.6 million recorded in Q2, but the company did not provide broader full-year revenue or expense guidance in the supplied release.

Recent insider transactions

The supplied insider data reports no purchases or sales during the latest six-month period and total insider holdings of 14.54 million shares. Eight transactions dated June 3, 2026, were zero-price stock grants with reported values of $0; the latest quantified sales in the two-year disclosures occurred on January 6, 2026.

These disclosures describe the transactions but do not establish the insiders’ reasons for selling.

Risks investors should watch

• Commercial adoption: AVLAYAH’s first full quarter produced $3.6 million in revenue, making execution against the $10 million-to-$12 million Q3 forecast an important measure of patient access and launch progress.
• Initial product economics may not persist: Cost of goods sold currently benefits from inventory whose manufacturing costs were previously expensed through R&D. Reported product margins may change as that inventory is depleted.
• Continued operating losses: AVLAYAH revenue remains small relative to Denali’s quarterly R&D and commercial expense base, even after the Priority Review Voucher sale strengthened liquidity.
• Regulatory and clinical execution: AVLAYAH received accelerated approval and still requires confirmatory evidence, while the rest of Denali’s pipeline remains investigational.
• Pipeline delays and setbacks: DNL151 failed its LUMA endpoints, DNL593 results moved into 2027 and Takeda ended the DNL593 partnership, increasing the importance of upcoming clinical milestones across the remaining portfolio.

Summary

Denali’s Q2 2026 results established AVLAYAH as its first source of product revenue and showed expanding payer and physician engagement, but the company continues to operate with substantial losses as it funds commercialization and a broad clinical pipeline. The next major financial test is whether AVLAYAH reaches its Q3 revenue guidance, while confirmatory work for the product and multiple 2027 clinical readouts will shape the longer-term outlook.